Drug Profile
Research programme: matrix metalloproteinase inhibitors - Pharmahungary
Alternative Names: MMPharma™ project - PharmahungaryLatest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Pharmahungary Group
- Class Small molecules
- Mechanism of Action Matrix metalloproteinase 13 inhibitors; Matrix metalloproteinase 2 inhibitors; Matrix metalloproteinase 9 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Myocardial infarction
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Myocardial-infarction in Hungary
- 05 Jul 2016 Research programme: matrix metalloproteinase inhibitors - Pharmahungary is available for licensing - http://www.pharmahungary.com/mmp-inhibitors
- 05 Jul 2016 Early research in Myocardial infarction in Hungary (unspecified rout